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Esthesioneuroblastoma (ENB) is a rare malignant tumor that commonly develops in the upper nasal cavity. Standard treatment is
not established, especially in locally advanced disease which portends the worse prognosis. Hereby, we report a case of a 27-year-
old, 23-week pregnant woman, with a 2-month history of progressively growing right cervical lymphadenopathy, nasal obstruction,
anosmia, frequent episodes of epistaxis, and right frontal headache. Imagiological evaluation revealed a lesion with 7×5,2×3,2 cm in
the nasal fossae with extension to the ethmoidal complex and right olfactive fend and invasion of the endocranial compartment
associated with lymphadenopathy. The biopsy revealed a high-grade EBN. Neoadjuvant chemotherapy with cisplatin and
etoposide was administrated during pregnancy and continued after delivery up to 6 cycles of treatment with partial response.
Radiotherapy followed, with complete response. This case report is intended to highlight that a high grade of suspicion should
be kept in the presence of nonspecific symptoms of nasal obstruction, anosmia, facial pain, and/or headache and focus that
chemotherapy is an important component of a combined-treatment modality for locally advanced ENB that can be used during
pregnancy in a lifesaving situation.
1. Background
Esthesioneuroblastoma (ENB), also referred to as olfactory
neuroblastoma (ONB), is a malignant neuroectodermal
tumor thought to originate from the olfactory membrane of
the sinonasal tract [1]. ENB is a rare tumor and most com-
monly develops in the upper nasal cavity in the region of
the cribriform plate [1]. Consequently, the most common
symptom is nasal obstruction that can be associated with epi-
staxis and pain [1–3]. Manifestations of locally advanced dis-
ease include anosmia, proptosis, facial pain, or frontal
headache due to invasion of adjacent structures [2]. There
is a slight male predominance and a bimodal age presenta-
tion in the second and sixth decade of life [1, 2]. The best
treatment options in advanced stages are not well defined
due to the rarity of the disease. The most frequent staging
system is the Kadish staging modified by Morita and col-
leagues [4]. A cervical lymph node or distant metastases
represent the most advanced stage of the disease—stage D.
The grading system developed by Hyams et al. [5] classifies
tumors in 4 groups based on mitotic activity, nuclear pleo-
morphism, rosette formation, necrosis, and the characteris-
tics of the fibrillary matrix. Both extent of disease and
grading appear to have a prognostic significance [6, 7]. We
report the case of a pregnant woman with a locally advanced
esthesioneuroblastoma (Figure 1).
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2. Case Presentation
A 27-year-old 8-week pregnant woman, with a history of
allergic rhinitis and atopic eczema, presented to a general
hospital with right nasal obstruction, right cervical lymph-
adenopathy, and pain in the right superior dental arcade. A
nonsteroidal anti-inflammatory drug was started with reso-
lution of the dental pain after one week of treatment. Two
months later, while maintaining a progressively growing
right cervical lymphadenopathy and right nasal obstruction,
the patient developed anosmia, frequent episodes of epi-
staxis, and right frontal headache. A fine needle biopsy of
the lymphadenopathy was performed with an inconclusive
result, revealing only the presence of inflammatory cells. A
core biopsy was then performed which revealed lymph node
metastasis from a poorly differentiated malignant neoplasm.
At the 23rd week of pregnancy, the patient was referred to
our hospital. On physical examination, the patient had a
voluminous right cervical lymphadenopathy with 15 cm
from levels Ib to V associated with cutaneous erythema as
well as right ocular oedema (Figure 2). A vegetant nonulcer-
ated lesion was detected on the nasopharynx occupying the
right nasal vestibulum. A biopsy of the lesion was performed.
Pathology’s result revealed respiratory epithelium with focal
involvement by small round blue cells, neuron-specific eno-
lase (NSE) positive, synaptophysin positive, PS 100 positive,
and AE1/AE3 and CD99 negative. The cranial and cervical
magnetic resonance images (MRI) revealed a lesion with
7×5,2×3,2 cm in the nasal fossae, ethmoidal complex, and
right olfactive fend with invasion of the endocranial com-
partment and the orbit and deviation of the internal rectum
muscle as well as extension to the nasopharynx lumen and
invasion of the sphenoidal sinus associated with lymphade-
nopathy in the retropharyngeal area and right II, III, IV,
and V levels (Figures 3 and 4). The patient was diagnosed
with a right esthesioneuroblastoma stage D in the modified
Kadish grading system [4] and grade III/IV in the Hyams
grading system [5].
The case was evaluated by a multidisciplinary team of
head and neck surgeons, medical oncologists, and radiation
oncologists. The multidisciplinary tumor board determined
that there was no indication to perform surgery due to local
extent of the disease. The patient was proposed to do sys-
temic treatment with chemotherapy followed by reevaluation
by the multidisciplinary tumor board. Treatment with cis-
platin 75mg/m2 on day 1 and etoposide 75mg/m2 on days
1 to 3, cycles every 28 days, was started after an appropriate
discussion with the patient’s obstetrician. The following pre-
medication before each treatment cycle was prescribed:
hydrocortisone 100mg, metoclopramide 10mg, and ondan-
setron 8mg. Additional treatment with daily folic acid, oral
iron, iodine supplementation, and prophylactic enoxaparin
was made as recommended by the obstetrician.
After the first cycle of treatment, a clinical reduction of
the lesion was noted (Figure 5). Concerning the baby devel-
opment, routine amniotic fluid assessment made by foetal
echography after the 2nd cycle of chemotherapy showed an
increase in systolic velocity in the Doppler midfoetal cerebral
artery (systolic peak > 1 5 MoMs for gestational age). This
finding was in favour with an established foetal anemia
and interpreted as a side effect of chemotherapy. Once
the foetus was stable (normal foetal biophysical profile),
a foetal lung maturation cycle with betamethasone was
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Figure 1: Timeline.
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performed according to protocol, and a decision to terminate
the pregnancy in an elective manner was made, thus avoiding
the worsening of the condition with a new cycle of chemo-
therapy. In addition, after 30 weeks of gestation, clinical sus-
picion of foetal anemia is an indication for termination of
pregnancy, avoiding invasive foetal studies. Thus, 21 days
after the second cycle of treatment and at 31 weeks of preg-
nancy, the patient delivered by caesarean a healthy baby
uneventfully. While hospitalized, the new-born presented a
normal development and no health problems were detected.
Fourteen days after the delivery, chemotherapy was
resumed at a full dose with cisplatin 100mg/m2 on day 1
and etoposide 100mg/m2 on days 1 to 3, cycles every 21 days.
After 4 cycles of treatment, a positron emission tomography-
computed tomography (PET-CT) and MRI were performed,
revealing a partial response. The patient completed 6 cycles
of treatment with good tolerance. The main toxicities
reported during treatment were grade 1 anemia, grade 1 nau-
sea, and emesis treated with oral iron, folic acid, andmetoclo-
pramide as needed.
The case was again discussed in a multidisciplinary
tumor board, and treatment with radiotherapy (RT) was pro-
posed. The patient performed 33 fractions of treatment with
volumetric modulated arc therapy (VMAT) at a dose of
70Gy to the neoplastic lesion, right retropharyngeal area,
and right cervical Ib to V levels and 50Gy to the left retro-
pharyngeal area, left cervical Ib to V levels, and left perinasal
area. The treatment had a duration of 45 days with good tol-
erance. The main toxicities were grade 2 dysphagia, grade 2
odynophagia, grade 2 xerostomia, grade 2 oral mucositis,
and grade 2 cervical dermatitis.
A period of clinical vigilance was started, and 12 weeks
after the last treatment of radiotherapy, a PET-CT was per-
formed revealing no radiopharmaceutical uptake. At the
12th month of follow-up, the baby is healthy and presents
a normal development. The patient is clinically well present-
ing as treatment sequels a grade 1 diminution of visual acu-
ity in the right eye, xerostomia grade 1, and cervical fibrosis
grade 1.
3. Conclusions
This clinical case demonstrates the challenge of diagnosis and
management of a rare and aggressive type of esthesioneuro-
blastoma in a pregnant woman. ENB is an uncommon tumor
that frequently presents with nonspecific symptoms such as
nasal obstruction and facial pain. The diagnosis is a challenge
for the clinicians due to the rarity and unspecificity of this
entity. Moreover, while the histologic diagnosis of a well-
differentiated tumor is quite evident, a less differentiated
form can be more laborious requiring additional markers
for the differential diagnosis among the group of small round
cell malignant neoplasms that can affect the sinonasal tract.
Olfactory neuroblastomas frequently express NSE and
synaptophysin and are negative for the expression of leuco-
cyte common antigen andCD99 [1]. The entities to be consid-
ered in differential diagnosis are neuroendocrine carcinomas,
melanoma, rhabdomyosarcoma, sinonasal undifferentiated
carcinoma, squamous cell carcinoma (including NUT carci-
noma), lymphoma, Ewing sarcoma, and metastatic tumors
[1, 8]. Both the nonspecific presentation and the rare histolog-
ical diagnosis contribute to a delay for the final diagnosis
which justifies that the majority of the ENB are found
in an advanced stage [9] as was the case in the clinical
case described.
The standard treatment for ENB has not been estab-
lished. The lack of prospective data due to its rarity and the
absence of molecular therapeutic targets are contributing
factors [10, 11]. Surgery followed by RT has been the most
Figure 4
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frequent treatment strategy and is associated with improved
overall survival compared with surgery or RT alone [12, 13].
Patients with cervical lymph node metastasis at presentation
have a worse prognosis despite combined-treatment modal-
ity [13], and the optimal management of these patients is
uncertain. This clinical case describes a 23-week pregnant
woman with a stage D ENB with cervical lymph node metas-
tasis from levels Ib to V. The aggressive phenotype of the dis-
ease characterized by a painful and rapidly growing locally
advanced tumor with lymph node metastasis and local inva-
sion of the orbit and endocranial compartment motivated the
decision to do treatment with neoadjuvant chemotherapy
followed by radiotherapy. In fact, there is some published
data that suggests that EBN is chemosensitive, and the addi-
tion of induction chemotherapy to a combined-treatment
modality in patients with advanced ENB may improve treat-
ment outcomes [10, 13]. The objective response to chemo-
therapy varied between 68% and 82% [10, 13–15], with a
5-year overall survival rate achieving 78% [13]. Various
chemotherapy agents have been used, being cisplatin-
based regimens (notably cisplatin and etoposide) frequently
chosen with encouraging responses [16]. In what concerns
the treatment strategy, the 23-week pregnancy of the
patient posed an increasing challenge since the diagnosis
of cancer during pregnancy is uncommon [17], and data
about chemotherapy in esthesioneuroblastoma during preg-
nancy is missing.
Exposure to some chemotherapeutic agents during the
second and third trimesters has not been associated with
increased risk of foetal malformations or major problems in
the short and long terms [17–19], contrarily to administra-
tion of chemotherapy during the first trimester of gestation
which is associated with an increased risk of foetal congenital
defects [17]. Cisplatin is usually safe for the foetus in the sec-
ond and third trimesters [20] for doses up to 75mg/m2 every
3 weeks [17]. There is evidence [21] that the rate of malfor-
mations after exposure to cisplatin in the first trimester is
about 20% but is reduced to 1% in the second and third tri-
mesters of pregnancy. Regarding etoposide, the data is more
limited reporting 3% of major malformations during the sec-
ond and third trimesters of pregnancy and a foetal growth
restriction in 24% of cases [21].
Considering that it was a lifesaving situation for both the
pregnant patient and her baby, the decision was to start treat-
ment with chemotherapy with a regimen of cisplatin and eto-
poside that was administered during the 24th to 31st week of
pregnancy. Furthermore, due to the high emetogenic poten-
tial of cisplatin-based regimens, it was essential to decide
the pretreatment associated with each cycle of chemotherapy
for prevention of chemotherapy-induced nausea and vomit-
ing in a pregnant patient. Both the dopamine D2 antagonist
metoclopramide and the serotonin 5-hydroxytryptamine
type (5-HT3) receptor antagonist ondansetron can be used
during pregnancy as there is no report of an increased risk
of pregnancy-related events [22]. In relation to corticoste-
roids, there is an association between oral clefts and use of
systemic steroids during the first trimester of pregnancy, so
its use should be cautious before 10 weeks of gestation [22].
Outside the first trimester of pregnancy, systemic corticoste-
roids can be used at the lowest effective dose and for the
shortest duration of time.
There were no complications during the neonatal period
and the 12th month period of follow-up for both the baby
and the mother, although a longer period of follow-up is nec-
essary to ascertain this good outcome. Due to the aggressive
nature of the esthesioneuroblastoma, clinical evaluation is
made on a monthly basis.
This case highlights that chemotherapy is an important
component of the multimodal treatment strategy of locally
advanced esthesioneuroblastoma and shows that in a lifesav-
ing situation, chemotherapy with cisplatin and etoposide can
be administered in the 2nd and 3rd trimesters of pregnancy.
Moreover, a prompt diagnosis is critical to achieve complete
remission of the disease especially in the case of a biologically
aggressive neoplasm. Prognosis of patients diagnosed with
cancer during pregnancy is usually comparable with non-
pregnant patients [17]; however, since recurrence of this type
of tumor may develop 10 or more years following initial
treatment [23, 24], a prolonged surveillance is mandatory.
This clinical case should be looked as a contribution to
future similar cases as it is a unique illustration of a rare
and aggressive esthesioneuroblastoma in a pregnant woman.
Abbreviations
ENB: Esthesioneuroblastoma
MRI: Magnetic resonance image
NSE: Neuron-specific enolase
OBN: Olfactory neuroblastoma
PET-CT: Positron emission tomography-computed
tomography
RT: Radiotherapy
VMAT: Volumetric modulated arc therapy.
Ethical Approval
All procedures performed were in accordance with the
ethical standards of the institutional and national research
committees and with the 1964 Helsinki Declaration and its
later amendments or comparable ethical standards.
Consent
Informed consent was obtained from the participant
included in the study.
Conflicts of Interest
The authors declare that they have no conflict of interest.
Authors’ Contributions
The first author wrote the article; CV and JD wrote and
reviewed the article. All authors read and approved the final
manuscript.
4 Case Reports in Oncological Medicine
References
[1] L. Barnes, J. W. Eveson, P. Reichart, and D. Sidransky, “Olfac-
tory neuroblastoma,” in Pathology and Genetics of Head and
Neck Tumours, IARC Press, Lyon, France, 2005.
[2] A. S. Abdelmeguid, “Olfactory neuroblastoma,” Current
Oncology Reports, vol. 20, no. 1, p. 7, 2018.
[3] J. P. Marinelli, J. R. Janus, J. J. Van Gompel et al., “Esthesio-
neuroblastoma with distant metastases: systematic review &
meta-analysis,” Head & Neck, vol. 40, no. 10, pp. 2295–2303,
2018.
[4] A. Morita, M. J. Ebersold, K. D. Olsen, R. L. Foote, J. E. Lewis,
and L. M. Quast, “Esthesioneuroblastoma: prognosis and man-
agement,” Neurosurgery, vol. 32, no. 5, pp. 706–715, 1993.
[5] V. Hyams, J. Batsakis, and L. Michaels, Tumors of the Upper
Respiratory Tract and Ear. Armed Forces Institute of Pathology
Fascicles, 2nd Series, American Registry of Pathology Press,
Washington, DC, USA, 1988.
[6] N. Konuthula, A. M. Iloreta, B. Miles et al., “Prognostic signif-
icance of Kadish staging in esthesioneuroblastoma: an analysis
of the National Cancer Database,” Head & Neck, vol. 39,
no. 10, pp. 1962–1968, 2017.
[7] B. A. Tajudeen, A. Arshi, J. D. Suh, M. St John, and M. B.
Wang, “Importance of tumor grade in esthesioneuroblastoma
survival: a population-based analysis,” JAMA Otolaryngology.
Head & Neck Surgery, vol. 140, no. 12, pp. 1124–1129, 2014.
[8] L. D. R. Thompson, “Small round blue cell tumors of the sino-
nasal tract: a differential diagnosis approach,” Modern Pathol-
ogy, vol. 30, Supplement 1, pp. S1–S26, 2017.
[9] R. Kumar, S. Ghoshal, D. Khosla et al., “Survival and failure
outcomes in locally advanced esthesioneuroblastoma: a single
centre experience of 15 patients,” European Archives of Oto-
Rhino-Laryngology, vol. 270, no. 6, pp. 1897–1901, 2013.
[10] A. Modesto, P. Blanchard, Y. G. Tao et al., “Multimodal treat-
ment and long-term outcome of patients with esthesioneuro-
blastoma,” Oral Oncology, vol. 49, no. 8, pp. 830–834, 2013.
[11] P. Czapiewski, M. Kunc, and J. Haybaeck, “Genetic and molec-
ular alterations in olfactory neuroblastoma: implications for
pathogenesis, prognosis and treatment,” Oncotarget, vol. 7,
no. 32, pp. 52584–52596, 2016.
[12] P. Dulguerov, A. S. Allal, and T. C. Calcaterra, “Esthesioneur-
oblastoma: a meta-analysis and review,” The Lancet Oncology,
vol. 2, no. 11, pp. 683–690, 2001.
[13] S. Y. Su, D. Bell, R. Ferrarotto et al., “Outcomes for olfactory
neuroblastoma treated with induction chemotherapy,” Head
& Neck, vol. 39, no. 8, pp. 1671–1679, 2017.
[14] D. W. Kim, Y. H. Jo, J. H. Kim et al., “Neoadjuvant etoposide,
ifosfamide, and cisplatin for the treatment of olfactory neuro-
blastoma,” Cancer, vol. 101, no. 10, pp. 2257–2260, 2004.
[15] Y. Mishima, E. Nagasaki, Y. Terui et al., “Combination chemo-
therapy (cyclophosphamide, doxorubicin, and vincristine with
continuous-infusion cisplatin and etoposide) and radiother-
apy with stem cell support can be beneficial for adolescents
and adults with estheisoneuroblastoma,” Cancer, vol. 101,
no. 6, pp. 1437–1444, 2004.
[16] V. A. Resto, D. W. Eisele, A. Forastiere, M. Zahurak, D. J. Lee,
and W. H.Westra, “Esthesioneuroblastoma: the Johns Hopkins
experience,” Head & Neck, vol. 22, no. 6, pp. 550–558, 2000.
[17] F. A. Peccatori, H. A. Azim, R. Orecchia et al., “Cancer, preg-
nancy and fertility: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up,” Annals of Oncology,
vol. 24, Supplement 6, pp. vi160–vi170, 2013.
[18] T. Vandenbroucke, M. Verheecke, M. Fumagalli, C. Lok, and
F. Amant, “Effects of cancer treatment during pregnancy on
fetal and child development,” The Lancet Child & Adolescent
Health, vol. 1, no. 4, pp. 302–310, 2017.
[19] F. Amant, T. Vandenbroucke, M. Verheecke et al., “Pediatric
outcome after maternal cancer diagnosed during pregnancy,”
The New England Journal of Medicine, vol. 373, no. 19,
pp. 1824–1834, 2015.
[20] A. McCormick and E. Peterson, “Cancer in pregnancy,”
Obstetrics and Gynecology Clinics of North America, vol. 45,
no. 2, pp. 187–200, 2018.
[21] National Toxicology Program, NTP Monograph on Develop-
mental Effects and Pregnancy Outcomes Associated with Can-
cer Chemotherapy Use during Pregnancy, U.S. Department of
health and Human services, 2013.
[22] M. Erick, J. T. Cox, and K. M. Mogensen, “ACOG practice
bulletin 189: nausea and vomiting of pregnancy,” Obstetrics
and Gynecology, vol. 131, no. 5, p. 935, 2018.
[23] P. D. Ward, J. A. Heth, B. G. Thompson, and L. J. Marentette,
“Esthesioneuroblastoma: results and outcomes of a single
institution’s experience,” Skull Base, vol. 19, no. 2, pp. 133–
140, 2009.
[24] E. M. Diaz Jr., R. H. Johnigan III, C. Pero et al., “Olfactory
neuroblastoma: the 22-year experience at one comprehensive
cancer center,” Head & Neck, vol. 27, no. 2, pp. 138–149,
2005.
5Case Reports in Oncological Medicine
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
